NCT06172036View on ClinicalTrials.gov

Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

January 20, 2024

Primary Completion Date

January 20, 2026

Study Completion Date

January 20, 2027

Conditions
Neoadjuvant ChemotherapyResectable Pancreatic Cancer
Interventions
DRUG

irinotecan liposome + oxaliplatin + 5-FU / LV

Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer

DRUG

Adebellizumab

Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer

All Listed Sponsors
lead

Zhejiang University

OTHER

NCT06172036 - Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab | Biotech Hunter | Biotech Hunter